TICKERNERD
Menu
IOVAIOVAHealthcare · Biotechnology

IOVA Stock Forecast: Iovance Biotherapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$8.60
+5.65% on the day

The 9 Wall Street analysts covering Iovance Biotherapeutics, Inc. hold a median 12-month price target of $10 — +16.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 90 of 100 as at 10 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$3.7B
Ticker Nerd rank
90 / 100
Median analyst target
$10
Analysts covering
9
Revenue$99.3M+65.7% y/y
Operating income−$51.9M
Net income−$47.3M
Free cash flow−$66.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.1%
1M
+32.5%
YTD
+215.0%
1Y
+255.4%
From 52W high
−4.3%
From 52W low
+375.1%
$1.81
$8.99
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IOVA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Iovance Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 10 Sept 2026
90 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
94
Value
89
Revisions
84
Growth
83
Momentum
83
Accruals
44
Issuance
43
Volatility
43
Size
28

Quality (94): The business earns solid, repeatable profits on what it owns.

Volatility (43): The share price moves around a lot.

Size (28): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IOVA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IOVA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00$14.00Oct 25Jan 26Apr 26Jul 26IOVAHigh $14Median $10Low $6

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
7 Buy2 Hold0 Sell
Low $6Median $10High $14

The green dot is the last close — the median target sits +16.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
25 Aug 2026TD CowenMaintainsBuy$7.00 → $10
20 Aug 2026UBSMaintainsNeutral$4.00 → $7.00
18 Aug 2026MizuhoMaintainsOutperform$10 → $11
7 Aug 2026BarclaysMaintainsOverweight$11 → $13
7 Aug 2026BarclaysMaintainsOverweight—
7 Aug 2026CitizensMaintainsMarket Outperform—
7 Aug 2026CitizensMaintainsMarket Outperform$5.00 → $8.00
8 May 2026Chardan CapitalMaintainsBuy—
7 May 2026Chardan CapitalMaintainsBuy$16 → $14
10 Apr 2026Chardan CapitalMaintainsBuy—
5 Mar 2026UBSMaintainsNeutral—
3 Mar 2026CitizensUpgradeMarket Outperform—
25 Feb 2026BarclaysMaintainsOverweight—
25 Feb 2026CitizensUpgradeMarket Outperform—
17 Dec 2025BarclaysMaintainsOverweight—
24 Nov 2025BarclaysMaintainsOverweight—
6 Nov 2025Chardan CapitalMaintainsBuy—
29 Oct 2025HC Wainwright & Co.MaintainsBuy—
19 Aug 2025HC Wainwright & Co.ReiteratesBuy—
8 Aug 2025Chardan CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IOVA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

IOVA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Iovance Biotherapeutics, Inc. returned +255.4% against +17.5% for the S&P 500, dividends included.

IOVA vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200250300350400Oct 25Jan 26Apr 26Jul 26IOVAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IOVA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
0
Fundamentals

Iovance Biotherapeutics, Inc. (IOVA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−7.5×

Cheaper than 92% of US stocks

Price / sales
11.3×

Cheaper than 13% of US stocks

Price / book
5.0×

Cheaper than 20% of US stocks

EV / EBITDA
−13.7×

Cheaper than 86% of US stocks

Growth & margins
Revenue growth (YoY)
65.7%

Higher than 89% of US stocks

Earnings growth (YoY)
65.7%

Higher than 79% of US stocks

Gross margin
56.1%

Higher than 69% of US stocks

Operating margin
−52.3%

Higher than 17% of US stocks

Net margin
−89.1%

Higher than 6% of US stocks

Returns & dividend
Return on equity
−40.4%

Higher than 24% of US stocks

Return on assets
−20.3%

Higher than 19% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Iovance Biotherapeutics, Inc. (IOVA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Iovance Biotherapeutics, Inc. has a market value of $3.7B and an enterprise value of $3.6B.

  • Revenue in the twelve months to 30 June 2026: $325.0M. The latest quarter grew 65.7% year on year.

  • Net income over the same four quarters: −$289.5M, a −89.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.73.

  • Free cash flow in the twelve months to 30 June 2026: −$296.4M.

  • Shares outstanding: 453.0M.

  • Trailing P/E: −7.5×; forward P/E: −28.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Iovance Biotherapeutics, Inc. employs 975 people — $333K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 10 Sept 2026

Data provided by Twelve Data

Peers

IOVA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IOVAIovance Biotherapeutics, Inc.$3.7B
90
VKTXViking Therapeutics, Inc.$3.7B
29
IDYAIDEAYA Biosciences, Inc.$3.5B
81
TNGXTango Therapeutics, Inc.$3.8B
44
TARSTarsus Pharmaceuticals, Inc.$3.5B
83
ABCLAbCellera Biologics, Inc.$3.4B
71
DYNDyne Therapeutics, Inc.$3.4B
24

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Iovance Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IOVA news & analysis

Iovance Biotherapeutics to Present at Upcoming Conferences

GlobeNewsWire · 4 Sept 2026neutral

Iovance Biotherapeutics announced that its senior leadership plans to present at several upcoming conferences. The biotech company, focused on developing tumor infiltrating lymphocyte therapies for cancer patients, did not specify the dates or names of the conferences in the excerpt.

Why it matters — IOVA watchers may be interested as these conference presentations could offer opportunities for the company to share updates on its TIL therapy pipeline with the investment and medical communities.

Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves

Zacks Investment Research · 27 Aug 2026positive

A Zacks Investment Research article highlights oncology innovation driving new treatment options, naming Iovance Biotherapeutics alongside Merit Medical and Kura as companies advancing cancer-focused therapies and technologies.

Why it matters — IOVA watchers would see the company recognised among leaders in evolving cancer care, underscoring its role in ongoing oncology innovation.

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen

Zacks Investment Research · 27 Aug 2026neutral

Zacks Investment Research published an Industry Outlook article highlighting Halozyme, Repligen, Iovance, Arcutis and Precigen. Iovance Biotherapeutics was named among the companies featured in the industry review.

Why it matters — The mention places Iovance in a broader industry outlook, giving IOVA watchers context on how the company is positioned within analyst coverage of its sector.

5 Biotech Stocks Worth Adding to Your Portfolio Now

Zacks Investment Research · 26 Aug 2026positive

Zacks Investment Research highlighted IOVA among five biotech stocks it considers worth adding to a portfolio, citing a strong portfolio and solid pipeline progress as positioning these companies in the volatile Biomedical and Genetics industry despite macro uncertainty.

Why it matters — IOVA watchers would care because the item identifies the company's pipeline progress and portfolio as strengths within the sector.

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewsWire · 21 Aug 2026neutral

Iovance Biotherapeutics granted inducement stock options covering 240,135 shares of common stock to twenty new non-executive employees on August 20, 2026, as approved under NASDAQ Listing Rule 5635(c)(4).

Why it matters — Inducement grants signal hiring activity and equity-based compensation for new hires, which can affect share dilution and reflect workforce expansion.

FAQ

Frequently asked questions about IOVA stock

What is the IOVA stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Iovance Biotherapeutics, Inc. have a median 12-month price target of $10, with estimates ranging from $6 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IOVA stock a buy right now?

Of the 9 analysts covering Iovance Biotherapeutics, Inc., 7 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Iovance Biotherapeutics, Inc. 90 out of 100 across roughly 4,600 US stocks as at 10 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IOVA?

As at 10 Sept 2026, Iovance Biotherapeutics, Inc. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (94 of 100).

Will IOVA stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +16.3% from the last close, and Ticker Nerd's factor model ranks Iovance Biotherapeutics, Inc. 90 out of 100 as at 10 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IOVA stock forecast for 2030?

No analyst covering Iovance Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IOVA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $14 over the next 12 months.

How has IOVA stock performed over the past year?

Iovance Biotherapeutics, Inc. returned +255.4% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Iovance Biotherapeutics, Inc. do?

Iovance Biotherapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing tumor infiltrating lymphocyte, or TIL, cell therapies for cancer.

What is the latest news on IOVA?

The most recent item we track (GlobeNewsWire, 4 Sept 2026): "Iovance Biotherapeutics to Present at Upcoming Conferences". Iovance Biotherapeutics announced that its senior leadership plans to present at several upcoming conferences. The biotech company, focused on developing tumor infiltrating lymphocyte therapies for cancer patients, did not specify the dates or names of the conferences in the excerpt.

Company

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing tumor infiltrating lymphocyte, or TIL, cell therapies for cancer. Its current portfolio centers on Amtagvi, an individualized cell therapy used in advanced melanoma, and Proleukin, which supports the treatment regimen. The company also advances investigational TIL-based programs for other solid tumors, including cervical cancer, non-small cell lung cancer, endometrial cancer, and head and neck squamous cell carcinoma. Iovance Biotherapeutics operates as an oncology-focused cell therapy platform, combining manufacturing, clinical development, and commercialization capabilities to deliver personalized immunotherapies for patients with difficult-to-treat cancers. Headquartered in San Carlos, California, it plays a specialized role in the broader biopharmaceutical market by bringing autologous immune-cell therapies into routine clinical use.

CEO Dr. Frederick G. Vogt Esq., J.D., Ph.D. · 975 employees · United States · https://www.iovance.com